Symbol | Exchange | Currency |
|---|
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Neutral | Sell | Sell |
| Technical Indicators | Buy | Sell | Sell | Sell | Sell |
| Summary | Buy | Neutral | Neutral | Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 157.70 | 161.28 | 157.34 | -1.24 | -0.78% | 25.81M | London | |||
| 1,644.50 | 1,661.00 | 1,629.50 | -5.00 | -0.30% | 682.91K | London | |||
| 73.00 | 75.00 | 73.00 | -1.00 | -1.35% | 462.76K | London | |||
| 5.51 | 5.30 | 5.30 | +0.05 | +0.92% | 4.83M | London | |||
| 127.04 | 127.52 | 126.42 | +0.54 | +0.43% | 25.34M | London | |||
| 436.80 | 452.80 | 436.80 | -2.80 | -0.64% | 102.41K | London | |||
| 9,270.00 | 9,342.00 | 9,188.00 | +70.0 | +0.76% | 197.84K | London | |||
| 1,326.00 | 1,362.50 | 1,323.50 | -10.00 | -0.75% | 904.61K | London | |||
| 365.40 | 365.40 | 358.00 | +10.30 | +2.90% | 1.37M | London | |||
| 537.30 | 541.10 | 532.00 | 0.00 | 0.00% | 29.59M | London | |||
| 253.90 | 257.40 | 252.40 | +1.10 | +0.43% | 1.61M | London | |||
| 299.00 | 309.00 | 299.00 | +1.00 | +0.34% | 28.92K | London | |||
| 406.00 | 407.50 | 405.00 | +2.00 | +0.49% | 489.77K | London | |||
| 403.70 | 415.90 | 395.00 | +8.70 | +2.20% | 2.97M | London | |||
| 162.80 | 168.40 | 159.40 | +1.00 | +0.62% | 3.27M | London |